Phospho-c-Jun (Ser63)抗体;Phospho-c-Jun (Ser63) Antibody—艾普蒂

+ +

•  

   

     Western blot analysis of c-Jun Phosphorylation in NIH/3T3 lysates treated with Anisomycin using Phospho-c-Jun (Ser63) antibody.    

  
  

•  

   

     Immunofluorescence analysis of Phospho-c-Jun (Ser63) in HeLa treated with anisomycin using Phospho-c-Jun (S63) antibody.    

  
  

•  

   

     Immunohistochemistry analysis of paraffin-embedded Human breast carcinoma using Phospho-c-Jun (S63) antibody.High-pressure and temperature Sodium Citrate pH 6.0 was used for antigen retrieval.    

  
  

The Phospho-c-Jun (Ser63) antibody is a specialized tool used to detect the activated form of c-Jun, a key component of the AP-1 transcription factor complex. c-Jun plays a central role in regulating cellular processes such as proliferation, differentiation, and apoptosis. Its activity is tightly controlled by phosphorylation, particularly at serine residues 63 and 73 within the transactivation domain. The phosphorylation at Ser63. mediated predominantly by c-Jun N-terminal kinases (JNKs), enhances c-Jun's transcriptional activity by promoting its dimerization with other AP-1 family members and facilitating interactions with coactivators. This post-translational modification is a critical event in stress response pathways, growth factor signaling, and oncogenic transformation.

The Phospho-c-Jun (Ser63) antibody specifically recognizes c-Jun when phosphorylated at Ser63. allowing researchers to study its activation status in various biological contexts. It is widely used in techniques like Western blotting, immunofluorescence, and immunohistochemistry to investigate JNK signaling dynamics, DNA damage responses, or inflammatory pathways. Dysregulation of c-Jun phosphorylation has been implicated in cancer, neurodegenerative diseases, and immune disorders, making this antibody valuable for both basic research and translational studies. Its specificity helps distinguish activated c-Jun from its unphosphorylated form, providing insights into pathway activation and potential therapeutic targeting of JNK/c-Jun signaling axes.